Corcept Therapeutics（CORT）株式概要
コーセプト・セラピューティクス・インコーポレイテッドはバイオ医薬品企業で、米国において重篤な内分泌疾患、腫瘍疾患、代謝疾患、神経疾患の治療薬の発見・開発に従事している。 詳細
CORT Community Fair Values
Create NarrativeSee what 114 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$63.53
FV
5.0% 割安 内在価値ディスカウント19.41%
Revenue growth p.a.
104
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Corcept Therapeutics Incorporated 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$60.36 |
| 52週高値 | US$91.00 |
| 52週安値 | US$28.66 |
| ベータ | 0.36 |
| 1ヶ月の変化 | 31.05% |
| 3ヶ月変化 | 66.65% |
| 1年変化 | -21.42% |
| 3年間の変化 | 161.87% |
| 5年間の変化 | 180.22% |
| IPOからの変化 | 393.54% |
最新ニュース
ナラティブの更新 • May 11
CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.Seeking Alpha • May 04
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Summary Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint. CORT 2026 revenue guidance was raised to $950–$1,050 million, driven by strong Lyforli uptake and robust Korlym sales, though risks include EU approval uncertainty and potential pricing pressures. Read the full article on Seeking AlphaRecent updates
ナラティブの更新 • May 11
CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.Seeking Alpha • May 04
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Summary Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint. CORT 2026 revenue guidance was raised to $950–$1,050 million, driven by strong Lyforli uptake and robust Korlym sales, though risks include EU approval uncertainty and potential pricing pressures. Read the full article on Seeking Alphaナラティブの更新 • Apr 25
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback
Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.ナラティブの更新 • Apr 11
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds
Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.ナラティブの更新 • Mar 27
CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk
Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.ナラティブの更新 • Mar 10
CORT: Future Generic Ruling And Oncology Data Will Drive Upside
Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.ナラティブの更新 • Feb 24
CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.ナラティブの更新 • Feb 09
CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside
Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.ナラティブの更新 • Jan 26
CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside
Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.ナラティブの更新 • Jan 10
CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.分析記事 • Jan 01
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...ナラティブの更新 • Dec 17
CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks
Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.分析記事 • Oct 07
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...株主還元
| CORT | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 3.7% | 2.6% | 2.5% |
| 1Y | -21.4% | 41.5% | 26.4% |
業界別リターン: CORT過去 1 年間で41.5 % の収益を上げたUS Pharmaceuticals業界を下回りました。
リターン対市場: CORTは、過去 1 年間で26.4 % のリターンを上げたUS市場を下回りました。
価格変動
| CORT volatility | |
|---|---|
| CORT Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: CORT 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CORTの 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1998 | 730 | Joseph Belanoff | www.corcept.com |
バイオ医薬品企業であるCorcept Therapeutics Incorporatedは、米国において重篤な内分泌疾患、腫瘍疾患、代謝疾患、神経疾患の治療薬の創薬・開発に取り組んでいる。同社は、2型糖尿病または耐糖能異常を有し、手術に失敗した、あるいは手術の候補とならない内因性クッシング症候群の成人患者において、高コルチゾール血症に続発する高血糖を治療する経口薬コリズムを提供している。また、高コルチゾール血症患者を対象とした選択的コルチゾール調節薬relacorilant、代謝機能障害関連脂肪肝炎を対象としたフェーズ1b試験中の選択的コルチゾール調節薬miricorilant、ルー・ゲーリッグ病治療のためのrelacorilant、nenocorilant、miricorilant、dazucorilantといった独自の選択的コルチゾール調節薬のポートフォリオも開発している。同社は1998年に設立され、カリフォルニア州レッドウッドシティに本社を置いている。
Corcept Therapeutics Incorporated 基礎のまとめ
| CORT 基礎統計学 | |
|---|---|
| 時価総額 | US$6.46b |
| 収益（TTM） | US$46.68m |
| 売上高(TTM) | US$769.10m |
138.8x
PER（株価収益率8.4x
P/SレシオCORT は割高か？
公正価値と評価分析を参照収益と収入
| CORT 損益計算書（TTM） | |
|---|---|
| 収益 | US$769.10m |
| 売上原価 | US$13.46m |
| 売上総利益 | US$755.64m |
| その他の費用 | US$708.96m |
| 収益 | US$46.68m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.43 |
| グロス・マージン | 98.25% |
| 純利益率 | 6.07% |
| 有利子負債／自己資本比率 | 0% |
CORT の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 05:07 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Corcept Therapeutics Incorporated 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18
| アナリスト | 機関 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |